I am still focused discussing the subject of ALXN because of their current position....
I was not suggesting the biosimilars to Soliris are the future of direction for complement winners.
I am suggesting that biosimilars are nearterm speed-bumps for ALXN, their unit-pricing, their reluctance to discount, and their sales volume and profits.
Patients will fare better and the investors who now swear by Alexion will be more prone to look elsewhere for successful complement companies that are growing, instead of shrinking.